Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine

被引:6
|
作者
Ceccon, Garry [1 ,2 ]
Wollring, Michael [1 ,2 ]
Brunn, Anna [2 ,3 ]
Deckert, Martina [2 ,3 ]
Waldschmidt, Dirk [2 ,4 ,6 ,7 ,8 ,9 ]
Fink, Gereon R. [1 ,2 ,5 ]
Galldiks, Norbert [1 ,2 ,5 ,6 ,7 ,8 ,9 ]
机构
[1] Univ Cologne, Fac Med, Dept Neurol, Cologne, Germany
[2] Univ Cologne, Univ Hosp Cologne, Cologne, Germany
[3] Univ Cologne, Fac Med, Dept Neuropathol, Cologne, Germany
[4] Univ Cologne, Fac Med, Dept Hepato & Gastroenterol, Cologne, Germany
[5] Forschungszentrum Julich, Inst Neurosci & Med INM 3, Leo Brandt Str 5, DE-52425 Julich, Germany
[6] Univ Aachen, Ctr Integrated Oncol CIO, Aachen, Germany
[7] Univ Bonn, Bonn, Germany
[8] Univ Cologne, Cologne, Germany
[9] Univ Duesseldorf, Dusseldorf, Germany
来源
CASE REPORTS IN ONCOLOGY | 2020年 / 13卷 / 01期
关键词
Blood-brain barrier; Leptomeningeal metastasis; Carcinomatous meningitis; FOLFIRINOX; ALBUMIN-BOUND PACLITAXEL; BREAST-CANCER; PHASE-II; NEOPLASTIC MENINGITIS; NEOADJUVANT TRIAL; BRAIN; CHEMOTHERAPY; TRASTUZUMAB; COMBINATION; TUMOR;
D O I
10.1159/000504697
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Leptomeningeal carcinomatosis is an extremely rare, but devastating complication in pancreatic cancer patients with a poor prognosis despite multimodal treatment. We present a 51-year-old male patient with the very rare condition of leptomeningeal carcinomatosis originating from pancreatic cancer. He presented to our hospital with severe headache and neck stiffness 30 months after systemic chemotherapy. Cerebral and spinal MRI as well as cerebrospinal fluid examination confirmed the diagnosis of leptomeningeal carcinomatosis. The patient responded to gemcitabine plus nab-paclitaxel in terms of elimination of tumor cells from the CSF and concurrent clinical improvement for 3 months. The observed findings suggest that the combination of gemcitabine plus nab-paclitaxel is potentially effective in affected cerebrospinal fluid of pancreatic carcinoma patients.
引用
收藏
页码:35 / 42
页数:8
相关论文
共 50 条
  • [21] Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel
    Ide, Yasushi
    Otsuka, Taiga
    Shimokawa, Mototsugu
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Arima, Shiho
    Fukahori, Masaru
    Makiyama, Akitaka
    Shinohara, Yudai
    Ueno, Shohei
    Taguchi, Hiroki
    Honda, Takuya
    Shibuki, Taro
    Nio, Kenta
    Ureshino, Norio
    Mizuta, Toshihiko
    Mitsugi, Kenji
    Shirakawa, Tsuyoshi
    ANTICANCER RESEARCH, 2023, 43 (04) : 1817 - 1826
  • [22] Nab-paclitaxel plus gemcitabine for unresectable pancreatic cancer: A pooled meta-analysis
    Zhang, Y.
    Shi, S.
    Yu, X.
    ANNALS OF ONCOLOGY, 2018, 29
  • [23] FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure
    Matsumoto, Toshihiko
    Kurioka, Yusuke
    Okazaki, Ukyo
    Matsuo, Yu
    Kimura, Shogo
    Miura, Kou
    Tsuduki, Takao
    Takagi, Shinjiro
    Takatani, Masahiro
    Morishita, Hirofumi
    PANCREAS, 2020, 49 (04) : 574 - 578
  • [24] Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
    Junko Tahara
    Kyoko Shimizu
    Nao Otsuka
    Junichi Akao
    Yukiko Takayama
    Katsutoshi Tokushige
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 245 - 250
  • [25] Feasibility of Combination Therapy with Nab-paclitaxel Plus Gemcitabine in Patients with Recurrent Pancreatic Cancer
    Kawaida, Hiromichi
    Kono, Hiroshi
    Amemiya, Hidetake
    Saitou, Ryou
    Yamamoto, Atsushi
    Hosomura, Naohiro
    Watanabe, Mitsuaki
    Kimura, Ayako
    Furuya, Shinji
    Shimizu, Hiroki
    Akaike, Hidenori
    Kawaguchi, Yoshihiko
    Sudo, Makoto
    Itakura, Jun
    Hayakawa, Hiroshi
    Shindo, Hiroko
    Takahashi, Ei
    Takano, Shinichi
    Fukasawa, Mitsuharu
    Ichikawa, Shintaro
    Fujii, Hideki
    Ichikawa, Daisuke
    ANTICANCER RESEARCH, 2018, 38 (11) : 6537 - 6542
  • [26] Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer
    Tahara, Junko
    Shimizu, Kyoko
    Otsuka, Nao
    Akao, Junichi
    Takayama, Yukiko
    Tokushige, Katsutoshi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (02) : 245 - 250
  • [27] Treatment outcomes of gemcitabine plus nab-paclitaxel in pancreatic cancer patients with malignant ascites
    Inoue, Kanae
    Fukushi, Koh
    Yamaguchi, Shota
    Taira, Tomonao
    Shibuki, Taro
    Satake, Tomoyuki
    Watanabe, Kazuo
    Sasaki, Mitsuhito
    Imaoka, Hiroshi
    Mitsunaga, Shuichi
    Ikeda, Masafumi
    PANCREATOLOGY, 2024, 24 (04) : 616 - 623
  • [28] Comparative effectiveness of gemcitabine vs gemcitabine plus nab-paclitaxel vs FOLFIRINOX for unresectable pancreatic cancer
    Yamamoto, Shun
    Ueno, Hideki
    Tanaka, Midori
    Inagaki, Yuji
    Ohba, Akihiro
    Sakamoto, Yasunari
    Kondo, Shunsuke
    Morizane, Chigusa
    Okusaka, Takuji
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] A modified regimen of nab-paclitaxel and gemcitabine in advanced pancreatic cancer
    Osman, M. A. M.
    McDermott, R.
    Fennelly, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer
    Borazanci, Erkut
    Von Hoff, Daniel D.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 8 (07) : 739 - 747